Smriti Kundu-Raychaudhuri1,2, Anupam Mitra2,3, Ananya Datta-Mitra1,2, Abhijit J Chaudhari4, Siba P Raychaudhuri1,2. 1. Division of Rheumatology, Allergy and Clinical Immunology, School of Medicine, University of California Davis, Davis, California, USA. 2. VA Northern California Health Care System, Sacramento, California, USA. 3. Division of Dermatology, School of Medicine, University of California Davis, Sacramento, California, USA. 4. Department of Radiology, School of Medicine, University of California Davis, Sacramento, California, USA.
Abstract
AIM: To quantify the progression and severity of mouse collagen-induced arthritis (CIA) using an in vivo imaging tool, (18) F-fluorodeoxyglucose ((18) F-FDG) PET/CT and validate it against gold standard 'histopathological' evaluation. METHOD: The PET radiotracer (18) F-FDG, a marker for glucose metabolism, was injected in mice at different stages of CIA and the radiotracer distribution was imaged using a PET scanner. A sequential CT scan provided correlated anatomy. Radiotracer concentration was derived from PET/CT images for individual limb joints and on a per-limb basis at different stages of the disease. The imaging outcomes were subjected to correlation analysis with concurrently measured clinical and histological score. RESULTS: Clinical and histological score, and hence disease severity, showed a strong linear correlation (r(2) = 0.71, P = 0.001 and r(2) = 0.87, P < 0.001, respectively) with radiotracer concentration measured from PET/CT during the progression of CIA. CONCLUSIONS: The strong positive correlation of the (18) F-FDG PET/CT findings with the histopathological evaluation at different stages of the disease suggest the potential of this imaging tool for the non-invasive assessment of progression and severity in mouse autoimmune arthritis. Thus, in preclinical studies, (18) F-FDG PET/CT can be considered as a non-invasive tool to develop novel therapies of inflammatory arthritis.
AIM: To quantify the progression and severity of mouse collagen-induced arthritis (CIA) using an in vivo imaging tool, (18) F-fluorodeoxyglucose ((18) F-FDG) PET/CT and validate it against gold standard 'histopathological' evaluation. METHOD: The PET radiotracer (18) F-FDG, a marker for glucose metabolism, was injected in mice at different stages of CIA and the radiotracer distribution was imaged using a PET scanner. A sequential CT scan provided correlated anatomy. Radiotracer concentration was derived from PET/CT images for individual limb joints and on a per-limb basis at different stages of the disease. The imaging outcomes were subjected to correlation analysis with concurrently measured clinical and histological score. RESULTS: Clinical and histological score, and hence disease severity, showed a strong linear correlation (r(2) = 0.71, P = 0.001 and r(2) = 0.87, P < 0.001, respectively) with radiotracer concentration measured from PET/CT during the progression of CIA. CONCLUSIONS: The strong positive correlation of the (18) F-FDG PET/CT findings with the histopathological evaluation at different stages of the disease suggest the potential of this imaging tool for the non-invasive assessment of progression and severity in mouseautoimmune arthritis. Thus, in preclinical studies, (18) F-FDG PET/CT can be considered as a non-invasive tool to develop novel therapies of inflammatory arthritis.
Authors: Gerhard W Goerres; Adrian Forster; Daniel Uebelhart; Burkhardt Seifert; Valerie Treyer; Beat Michel; Gustav K von Schulthess; Achim H Kaim Journal: Clin Nucl Med Date: 2006-07 Impact factor: 7.794
Authors: Ricardo T Paniagua; Orr Sharpe; Peggy P Ho; Steven M Chan; Anna Chang; John P Higgins; Beren H Tomooka; Fiona M Thomas; Jason J Song; Stuart B Goodman; David M Lee; Mark C Genovese; Paul J Utz; Lawrence Steinman; William H Robinson Journal: J Clin Invest Date: 2006-09-14 Impact factor: 14.808
Authors: Ingo M Irmler; Thomas Opfermann; Peter Gebhardt; Mieczyslaw Gajda; Rolf Bräuer; Hans P Saluz; Thomas Kamradt Journal: Arthritis Res Ther Date: 2010-11-03 Impact factor: 5.156
Authors: A Mitra; S Kundu-Raychaudhuri; C Abria; A Rona; A J Chaudhari; S P Raychaudhuri Journal: Clin Exp Immunol Date: 2017-02-24 Impact factor: 4.330
Authors: Christine Czegley; Clarissa Gillmann; Christine Schauer; Lisa Seyler; Christiane Reinwald; Madelaine Hahn; Michael Uder; Katja Jochmann; Elisabeth Naschberger; Michael Stock; Georg Schett; Tobias Bäuerle; Markus H Hoffmann Journal: Dis Model Mech Date: 2018-08-30 Impact factor: 5.758